Poxel announces positive results from phase 2a nash trial with pxl770, an oral first-in-class direct ampk activator

Poxel sa (euronext: poxel - fr0012432516), a biopharmaceutical company focused on the development of innovative treatments for metabolic disorders, in

MDGL Ratings Summary

MDGL Quant Ranking